Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress
SOUTH SAN FRANCISCO, May 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), a Phase 2, open-label clinical trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM), were presented in a Late Breaking Clinical Trial session at Heart Failure 2023 an International Congress of the European Society of Cardiology taking place online and in Prague, Czech Republic from May 20, 2023 – May 23, 2023.
- We look forward to advancing aficamten into a Phase 3 clinical trial in patients with nHCM which is expected to begin in the second half of this year.”
The new data from Cohort 4, presented today by Ahmad Masri, M.D. - At 10 weeks, treatment with aficamten was associated with an average improvement in KCCQ-CSS of 10.6 points (p
- Additionally, 56% of patients demonstrated improvement of ≥1 New York Heart Association (NYHA) Functional Class (p = 0.011) (Figure 2).
- Four patients (9.8%) had serious adverse events, including one previously reported death, and none were attributed to aficamten.